Hirata, Amanda Soares 
; Clair, James J. La ; Jimenez, Paula C. ; Costa-Lotufo, Letícia Veras ; Fenical, William
Fonte: Marine Drugs. Unidade: ICB
Assuntos: FARMACOLOGIA, CÉLULAS CULTIVADAS DE TUMOR, APOPTOSE, PRODUTOS NATURAIS, MELANOMA, NEOPLASIAS CUTÂNEAS, MOLÉCULA, INFECÇÕES BACTERIANAS GRAM-POSITIVAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
HIRATA, Amanda Soares et al. Preclinical development of seriniquinones as selective dermcidin modulators for the treatment of melanoma. Marine Drugs, v. 20, n. 5, p. 1-13, 2022Tradução . . Disponível em: https://doi.org/10.3390/md20050301. Acesso em: 09 nov. 2024.APA
Hirata, A. S., Clair, J. J. L., Jimenez, P. C., Costa-Lotufo, L. V., & Fenical, W. (2022). Preclinical development of seriniquinones as selective dermcidin modulators for the treatment of melanoma. Marine Drugs, 20( 5), 1-13. doi:10.3390/md20050301NLM
Hirata AS, Clair JJL, Jimenez PC, Costa-Lotufo LV, Fenical W. Preclinical development of seriniquinones as selective dermcidin modulators for the treatment of melanoma [Internet]. Marine Drugs. 2022 ; 20( 5): 1-13.[citado 2024 nov. 09 ] Available from: https://doi.org/10.3390/md20050301Vancouver
Hirata AS, Clair JJL, Jimenez PC, Costa-Lotufo LV, Fenical W. Preclinical development of seriniquinones as selective dermcidin modulators for the treatment of melanoma [Internet]. Marine Drugs. 2022 ; 20( 5): 1-13.[citado 2024 nov. 09 ] Available from: https://doi.org/10.3390/md20050301
